Skip to main content
SpringerLink
Log in

Principles of Chemotherapy in Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1011 Accesses

Abstract

Hodgkin lymphoma (HL) is one of the first malignancies that was curable using combination chemotherapy. The principles of combination chemotherapy used in treating many malignancies were developed for the treatment of HL. The concept of combination chemotherapy, originally developed for childhood acute lymphoblastic leukemia, was applied to advanced-stage HL by DeVita and colleagues at the US National Cancer Institute when they developed the MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) regimen. The ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) regimen was developed by Bonadonna and colleagues at the Milan Tumor Institute. Trials using combinations of the two regimens, either alternated monthly or in hybrid form, improved progression-free survival (PFS), although not overall survival (OS), as compared with MOPP alone. Further trials showed that this PFS advantage was attributable to ABVD alone rather than to the combination, which led to the establishment of ABVD as a standard regimen. Further improvement in PFS was demonstrated using the more intensive escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen, although it had higher toxicity. The combination of the antibody-drug conjugate brentuximab vedotin with AVD improved short-term PFS as compared with ABVD. Chemotherapy regimens such as ABVD in combination with radiation therapy improved PFS, although not OS, in several clinical trials for early-stage HL patients. More recently, chemotherapy alone provided excellent results in this population. Interim positron emission tomography/computed tomography (PET/CT) response as a biomarker during chemotherapy has been used to tailor therapy in recent clinical trials. High-dose chemotherapy with autologous stem cell support is still employed as a potentially curative second-line treatment. New effective immune therapies are also under investigation in combination with or substituting for chemotherapy. The objective of current research is to maintain or improve excellent treatment results while minimizing treatment risks.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wilkinson JF, Fletcher F (1947) Effect of beta-chloroethylamine hydrochlorides in leukaemia, Hodgkin’s disease, and polycythaemia vera; report on 18 cases. Lancet 2(6476):540–545

    Article  CAS  PubMed  Google Scholar 

  2. Papac RJ (2001) Origins of cancer therapy. Yale J Biol Med 74(6):391–398

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Zubrod CG (1979) Historic milestones in curative chemotherapy. Semin Oncol 6:490–505

    CAS  PubMed  Google Scholar 

  4. Gross R, Lambers K (1958) Erste erfarhungen in der Behandlung malignen tumoren mit einem neuen N-lost phosphamidester. Dtsch Med Wschr 83:458–462

    Article  CAS  PubMed  Google Scholar 

  5. Rotolo V (1968) Vincaleukoblastine in the therapy of malignant neoplasms. Friuli Med 23(1):31–52

    CAS  PubMed  Google Scholar 

  6. Mathe G, Cattan A, Amiel JL, Schwarzenberg L, Schneider M (1969) Experimental therapeutic trials of leukemia and hematosarcomas: technologic and philosophic aspects. Ann N Y Acad Sci 164(3):776–792

    Article  CAS  PubMed  Google Scholar 

  7. Burchenal JH (1975) From wild fowl to stalking horses: alchemy in chemotherapy. Cancer 35:1121–1135

    Article  CAS  PubMed  Google Scholar 

  8. Gilman A (1963) The initial clinical trial of nitrogen mustard. Am J Surg 105(574):578

    Google Scholar 

  9. Wagener DJT (2009) The history of oncology. Springer, Berlin

    Google Scholar 

  10. Mathe G, Schweisguth O, Schneider M, Amiel JL, Cattan A, Schwarzenberg L et al (1964) Value of vincaleukoblastine in the treatment of Hodgkin’s disease and other hematosarcomas and leukemias. Sem Ther 40(5):320–324

    CAS  PubMed  Google Scholar 

  11. Tubiana M, Henry-Amar M, Hayat M, Breur K, Werf-Messing B, Burgers M (1979) Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin’s disease. Eur J Cancer 15(5):645–657

    Article  CAS  PubMed  Google Scholar 

  12. Rosenberg SA, Kaplan HS (1966) Evidence for an orderly progression in the spread of Hodgkin’s disease. Cancer Res 26(6):1225–1231

    CAS  PubMed  Google Scholar 

  13. Tubiana M, Hayat M, Henry-Amar M, Breur K, van der Werf MB, Burgers M (1981) Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin’s disease. Eur J Cancer 17(3):355–363

    Article  CAS  PubMed  Google Scholar 

  14. Bergsagel DE, Alison RE, Bean HA, Brown TC, Bush RS, Clark RM et al (1982) Results of treating Hodgkin’s disease without a policy of laparotomy staging. Cancer Treat Rep 66:717–731

    CAS  PubMed  Google Scholar 

  15. Selby P, McElwain TJ, Canellos G (1987) Chemotherapy for Hodgkin’s disease. Section I: MOPP and its variants. In: Selby P, McElwain TJ (eds) Hodgkin’s disease. Blackwell, Oxford

    Google Scholar 

  16. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Johnson PW, Federico M, Fossa A, Barrington SF, Kirkwood A, Roberts TH et al (2013) Response rates and toxicity of response-adapted therapy in advanced Hodgkin lymphoma: initial results. From The International RATHL Study. Hematologica 98(s2):2

    Google Scholar 

  18. Bernard J (1966) Current general principles of the treatment of Hodgkin’s disease, lymphosarcoma and reticulosarcoma. Rev Prat 16(7):871–879

    CAS  PubMed  Google Scholar 

  19. Lacher MJ, Durant JR (1965) Combined vinblastine and CHLORAMBUCIL therapy of HODGKIN’s disease. Ann Intern Med 62:468–476

    Article  CAS  PubMed  Google Scholar 

  20. DeVita VT Jr, Carbone PP (1967) Treatment of Hodgkin’s disease. Med Ann 36(4):232–234

    Google Scholar 

  21. DeVita VT, Serpick AA, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73(6):881–895

    Article  PubMed  Google Scholar 

  22. DeVita VT, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH et al (1980) Curability of advanced Hodgkin’s disease with chemotherapy. Ann Intern Med 92(5):587–595

    Article  PubMed  Google Scholar 

  23. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES et al (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4(9):1295–1306

    Article  CAS  PubMed  Google Scholar 

  24. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21):1478–1484

    Article  CAS  PubMed  Google Scholar 

  25. Carde P, MacKintosh FR, Rosenberg SA (1983) A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol 1(2):146–153

    Article  CAS  PubMed  Google Scholar 

  26. Frei E III, Luce JK, Gamble JF, Coltman CA Jr, Constanzi JJ, Talley RW et al (1973) Combination chemotherapy in advanced Hodgkin’s disease: induction and maintenance of remission. Ann Intern Med 79(3):376–382

    Article  PubMed  Google Scholar 

  27. Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A et al (1994) A randomized study in stage IIIB and IV Hodgkin’s disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer lymphoma cooperative group and Groupe Pierre-et-Marie-curie controlled clinical trial. J Clin Oncol 12(2):279–287

    Article  CAS  PubMed  Google Scholar 

  28. Carde P, Hayat M, Cosset JM, Somers R, Burgers JM, Sizoo W et al (1988) Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin’s disease: experience of the European Organization for Research and Treatment of Cancer. NCI Monogr 6:303–310

    Google Scholar 

  29. Young RC, Chabner BA, Canellos GP, Schein PS, DeVita VT (1973) Maintenance chemotherapy for advanced Hodgkin’s disease in remission. Lancet 301(7816):1339–1343

    Article  Google Scholar 

  30. Lowenbraun STAN, DeVita VT, Serpick AA (1970) Combination chemotherapy with nitrogen mustard, vincristine, Procarbazine and prednisone in previously treated patients with Hodgkin’s disease. Blood 36(6):704–717

    Article  CAS  PubMed  Google Scholar 

  31. Fisher RI, DeVita VT, Hubbard SP, Simon R, Young RC (1979) Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann Intern Med 90(5):761–763

    Article  CAS  PubMed  Google Scholar 

  32. Arseneau JC, Sponzo RW, Levin DL, Schnipper LE, Bonner H, Young RC et al (1972) Non lymphomatous malignant tumors complicating Hodgkin’s disease : possible association with intensive therapy. N Engl J Med 287(22):1119–1122

    Article  CAS  PubMed  Google Scholar 

  33. Weiden PL, Lerner KG, Gerdes A, Heywood JD, Fefer A, Thomas ED (1973) Pancytopenia and leukemia in Hodgkin’s disease: report of three cases. Blood 42(4):571–577

    Article  CAS  PubMed  Google Scholar 

  34. Sherins RJ, DeVita VT Jr (1973) Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Ann Intern Med 79(2):216–220

    Article  CAS  PubMed  Google Scholar 

  35. Corder MP, Young RC, Brown RS, Devita VT (1972) Phytohemagglutinin-induced lymphocyte transformation: the relationship to prognosis of Hodgkin’s disease. Blood 39(5):595–601

    Article  CAS  PubMed  Google Scholar 

  36. Crowther D, Wagstaff J, Deakin D, Todd I, Wilkinson P, Anderson H et al (1984) A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin’s disease. J Clin Oncol 2(8):892–897

    Article  CAS  PubMed  Google Scholar 

  37. Nicholson WM, Beard ME, Crowther D, Stansfeld AG, Vartan CP, Malpas JS et al (1970) Combination chemotherapy in generalized Hodgkin’s disease. Br Med J 3(713):7–10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ranson MR, Radford JA, Swindell R, Dikin DP, Wilkinson PM, Harris M et al (1991) An analysis of prognostic factors in stage III and IV Hodgkin’s disease treated at a single centre with MVPP. Ann Oncol 2(6):83–89

    Article  Google Scholar 

  39. Dady PJ, McElwain TJ, Austin DE, Barrett A, Peckham MJ (1982) Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for hodgkin’s diseasechlvpp advanced HL. Br J Cancer 45:851–859

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. McElwain TJ, Toy J, Smith E, Peckham MJ, Austin DE (1977) A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin’s disease. Br J Cancer 36(276):280

    Google Scholar 

  41. Luce JK, Gamble JF, Wilson HE, Monto RW, Isaacs BL, Palmer RL et al (1971) Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer 28(2):306–317

    Article  CAS  PubMed  Google Scholar 

  42. Bonadonna G, Monfardini S (1969) Cardiac toxicity of daunorubicin. Lancet 1(7599):837

    Article  CAS  PubMed  Google Scholar 

  43. Bonadonna G, Monfardini S, Oldini C (1969) Comparative effects of vinblastine and procarbazine in advanced Hodgkin’s disease. Eur J Cancer (1965) 5(4):393–402

    Article  CAS  Google Scholar 

  44. Frei E, Luce JK, Talley RW, Veitkvicius VK, Wilson HE (1972) 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Treat Rep 56(5):667–670

    Google Scholar 

  45. O'Bryan RM, Luce JK, Tailey RW, Gottlieb JA, Baker LH, Bonadonna G (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32(1):1–8

    Article  CAS  PubMed  Google Scholar 

  46. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36(1):252–259

    Article  CAS  PubMed  Google Scholar 

  47. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21(4):607–614

    Article  CAS  PubMed  Google Scholar 

  48. Boleti E, Mead GM (2007) ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 18(2):376–380

    Article  CAS  PubMed  Google Scholar 

  49. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 23(30):7614–7620

    Article  CAS  PubMed  Google Scholar 

  50. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C et al (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104(12):3483–3489

    Article  CAS  PubMed  Google Scholar 

  51. Canellos GP, Duggan D, Johnson J, Niedzwiecki D (2004) How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 22(8):1532–1533

    Article  PubMed  Google Scholar 

  52. Johnson P Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374(25):2419–2429

    Google Scholar 

  53. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307–1317

    CAS  PubMed  Google Scholar 

  54. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348(24):2386–2395

    Article  CAS  PubMed  Google Scholar 

  55. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341(8852):1051–1054

    Article  CAS  PubMed  Google Scholar 

  56. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359(9323):2065–2071

    Article  CAS  PubMed  Google Scholar 

  57. Hasenclever D, Brosteanu O, Gerike T, Loeffler M (2001) Modelling of chemotherapy: the effective dose approach. Ann Hematol 80(Suppl 3):B89–B94

    CAS  PubMed  Google Scholar 

  58. Hasenclever D, Loeffler M, Diehl V (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol 7(Suppl 4):95–98

    Article  PubMed  Google Scholar 

  59. Owadally WS, Sydes MR, Radford JA, Hancock BW, Cullen MH, Stenning SP et al (2010) Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Ann Oncol 21:568–573

    Article  CAS  PubMed  Google Scholar 

  60. Brosteanu O, Hasenclever D, Loeffler M, Diehl V, Group GH (2004) Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin’s disease. Ann Hematol 83(3):176–182

    Article  CAS  PubMed  Google Scholar 

  61. Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F et al (2009) Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood 113(14):3307–3313

    Article  CAS  PubMed  Google Scholar 

  62. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD et al (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554

    Article  PubMed  Google Scholar 

  63. Henry-Amar M, Hayat M, Meerwaldt JH, Burgers M, Carde P, Somers R et al (1990) Causes of death after therapy for early stage Hodgkin’s disease entered on EORTC protocols. EORTC lymphoma cooperative group. Int J Radiat Oncol Biol Phys 19(5):1155–1157

    Article  CAS  PubMed  Google Scholar 

  64. Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, Van den Beltdusebout AW, Van Kerkhoff EHM et al (1994) 2nd cancer risk following hodgkins-disease - a 20-year follow-up-study. J Clin Oncol 12(2):312–325

    Article  PubMed  Google Scholar 

  65. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ (1995) Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 13(5):1080–1088

    Article  CAS  PubMed  Google Scholar 

  66. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D et al (2000) Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkinís disease: eastern cooperative oncology group pilot study E1492. J Clin Oncol 18(5):972

    Article  CAS  PubMed  Google Scholar 

  67. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20(3):630–637

    PubMed  Google Scholar 

  68. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C et al (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23(36):9198–9207

    Article  CAS  PubMed  Google Scholar 

  69. Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW et al (2009) Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute lymphoma group study ISRCTN 64141244. J Clin Oncol 27(32):5390–5396

    Article  PubMed  Google Scholar 

  70. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD et al (2013) Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the eastern cooperative oncology group (E2496). J Clin Oncol 31(6):684–691

    Article  PubMed  Google Scholar 

  71. Radford JA, Rohatiner AZS, Ryder WDJ, Deakin DP, Barbui T, Lucie NP et al (2002) ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol 20(13):2988–2994

    Article  CAS  PubMed  Google Scholar 

  72. Green JA, Dawson AA, Fell LF, Murray S (1980) Measurement of drug dosage intensity in MVPP therapy in Hodgkin’s disease. Br J Clin Pharmacol 9:511–514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M et al (1997) BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s lymphoma study group. Ann Oncol 8(2):143–148

    Article  CAS  PubMed  Google Scholar 

  74. Diehl V, Haverkamp H, Mueller R, Mueller-Hermelink H, Cerny T, Markova J et al (2009) Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): final analysis of the HD12 trial of the German Hodgkin study group (GHSG). ASCO Meet Abst 27(15S):8544

    Google Scholar 

  75. Engert A, Franklin J, Mueller RP, Eich HT, Gossmann A, Mueller-Hermelink HK et al (2006) HD12 randomised trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): an analysis of the German Hodgkin lymphoma study group (GHSG), University of Cologne, Cologne, Germany. ASH Annu Meet Abstr 108(11):99

    Google Scholar 

  76. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112(10):3989–3994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A et al (2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo studio Dei Linfomi trial. J Clin Oncol 27(5):805–811

    Article  PubMed  Google Scholar 

  78. Gianni AM, Rambaldi A, Zinzani P, Levis A, Brusamolino E, Pulsoni A et al (2008) Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. ASCO Meet Abstr 26(15 Suppl):8506

    Google Scholar 

  79. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V et al (2011) ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 365(3):203–212

    Article  CAS  PubMed  Google Scholar 

  80. Carde P, Karrasch M, Fortpied C, Brice P, Khaled HM, Caillot D et al (2012) ABVD (8cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin Lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. J Clin Oncol 30:abstr 8002

    Article  Google Scholar 

  81. von Tresckow B, Haverkamp H, Boll B, Eichenauer DA, Sasse S, Fuchs M et al (2013) Impact of dose reduction of bleomycin and vincristine in patients with advanced Hodgkin lymphoma treated with BEACOPP: A comprehensive analysis of the German Hodgkin Study Group (GHSG) HD12 and HD15 trials. Blood 122(21):Abstract 637

    Article  Google Scholar 

  82. Proctor SJ, Mackie M, Dawson A, Prescott B, Lucraft HL, Angus B et al (2002) A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin’s disease patients identified by the Scotland and Newcastle lymphoma group (SNLG) prognostic index: a Scotland and Newcastle lymphoma group study (SNLG HD III). Eur J Cancer 38(6):795–806

    Article  CAS  PubMed  Google Scholar 

  83. Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C et al (2003) High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol 21(12):2320–2325

    Article  CAS  PubMed  Google Scholar 

  84. Arakelyan N, Berthou C, Desablens B, De Guibert S, Delwail V, Moles MP et al (2008) Radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and Dacarbazine plus Myeloablative chemotherapy with autologous stem cell transplantation five-year results of a randomized trial on behalf of the GOELAMS group. Cancer 113(12):3323–3330

    Article  CAS  PubMed  Google Scholar 

  85. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068

    Article  PubMed  PubMed Central  Google Scholar 

  86. Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I et al (2014) In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol 32(25):2705–2711

    Article  PubMed  Google Scholar 

  87. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED et al (2011) Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood 117(20):5314–5320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607

    Article  CAS  PubMed  Google Scholar 

  89. Straus D, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schoder H et al (2016) Results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB/ALLIANCE 50604) (Abstract). Haematol J Eur Hematol Assoc 101:13. ISHL 10. Journal of the European Hematology Association. 101. Cologne, Germany: Ferrata Storti Foundation

    Google Scholar 

  90. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32(12):1188–1194

    Article  PubMed  Google Scholar 

  91. Andre MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(16):1786–1794

    Article  CAS  PubMed  Google Scholar 

  92. Fuchs M, Goergen H, Kobe C, Eich H, Baues C, Greil R et al (2018) PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin Study Group. Blood 132(Suppl 1):925

    Article  Google Scholar 

  93. Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M et al (2016) US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol 34(17):2020–2027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA et al (2018) PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390(10114):2790–2802

    Article  Google Scholar 

  95. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A et al (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378(4):331–344

    Article  CAS  PubMed  Google Scholar 

  96. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R et al (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25(19):2764–2769

    Article  CAS  PubMed  Google Scholar 

  97. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P et al (2003) A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98(2):310–314

    Article  CAS  PubMed  Google Scholar 

  98. Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT et al (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101(11):4285–4289

    Article  CAS  PubMed  Google Scholar 

  99. Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM et al (2008) Bortezomib and gemcitabine in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 19(10):1759–1764

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Younes A, Pro B, Fanale M, McLaughlin P, Neelapu S, Fayad L et al (2007) Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma. Blood 110(11):2566

    Google Scholar 

  101. Bonadonna G, Santoro A, Bonfante V, Valagussa P (1982) Cyclic delivery of MOPP and ABVD combinations in stage IV Hodgkin’s disease: rationale, background studies, and recent results. Cancer Treat Rep 66(4):881–887

    CAS  PubMed  Google Scholar 

  102. Radford JA, Crowther D, Rohatiner AZ, Ryder WD, Gupta RK, Oza A et al (1995) Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin’s disease. J Clin Oncol 13(9):2379–2385

    Article  CAS  PubMed  Google Scholar 

  103. Sutcliffe S, Wrigley PFM, Peto J, Lister TA, Stansfeld AG, Whitehouse JM et al (1978) MVPP chemotherapy regimen for advanced Hodgkin’s disease. Br Med J 6114:679–683

    Article  Google Scholar 

  104. Selby P, Patel P, Milan S, Meldrum M, Mansi J, Mbidde E et al (1990) ChlVPP combination chemotherapy for Hodgkin’s disease: long-term results. Br J Cancer 62(2):279–285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Johnson PWM, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS et al (2005) Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom lymphoma group LY09 trial (ISRCTN97144519). J Clin Oncol 23(36):9208–9218

    Article  CAS  PubMed  Google Scholar 

  106. Santoro A, Bonadonna G, Bonfante V, Valagussa P (1982) Alternating drug combinations in the treatment of advanced Hodgkin’s disease. N Engl J Med 306(13):770–775

    Article  CAS  PubMed  Google Scholar 

  107. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L et al (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol 14(5):1421–1430

    Article  CAS  PubMed  Google Scholar 

  108. Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R et al (2004) Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s lymphoma study group HD6 trial. Ann Oncol 15(2):276–282

    Article  CAS  PubMed  Google Scholar 

  109. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R (2003) T veer MB, Lybeert ML, et al. involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348(24):2396–2406

    Article  PubMed  Google Scholar 

  110. Klimo P, Connors JM (1985) MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin’s disease. J Clin Oncol 3(9):1174–1182

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    David Straus

  2. Department of Haematology, Prince of Wales Hospital, Randwick, NSW, Australia

    Mark Hertzberg

Authors
  1. David Straus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Hertzberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Straus .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University Hospital Cologne, Köln, Nordrhein-Westfalen, Germany

    Andreas Engert

  2. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Straus, D., Hertzberg, M. (2020). Principles of Chemotherapy in Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-32482-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32482-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32481-0

  • Online ISBN: 978-3-030-32482-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation